Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haloperidol + olanzapine
- Development stage
- Unknown
- Lead developer
- Janssen Pharmaceutica
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
A combination of two antipsychotic medications. Haloperidol is a first-generation (typical) antipsychotic that primarily blocks dopamine D2 receptors, while olanzapine is a second-generation (atypical) antipsychotic that blocks multiple receptors including dopamine, serotonin (5-HT2), histamine H-1, muscarinic, and alpha-1 receptors. This combination may be used for treating schizophrenia, acute psychosis, and symptoms related to amphetamine-type stimulants.
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on haloperidol + olanzapine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haloperidol + olanzapine.